U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird ...

Moderna (NASDAQ:MRNA) shares about 3% ahead of Wednesday market open after Goldman Sachs cut its rating on the stock to Neutral from Buy. The downgrade follows a series of negative revisions to ...

O n Wednesday, Goldman Sachs analyst Salveen Richter downgraded Moderna (NASDAQ:MRNA) stock from Buy to Neutral, significantly reducing the price target to $51 from the previous $99. Trading at ...

“S&P 500 annual return dispersion in 2024 rose to 70 percentage points, the highest level outside of recessions since 2007,” David Kostin, strategist at Goldman Sachs ... 20.5 Moderna Inc ...

Pharmaceutical giant Moderna Inc. (NASDAQ:MRNA) lost 7.28 percent of its value on Monday to end the day at $36.55 apiece as investors continued to sell off positions following Goldman Sachs ...

Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

Consistent in their evaluation, an analyst from UBS keeps a Buy rating on Moderna with a target price of $78. * In a cautious move, an analyst from Goldman Sachs downgraded its rating to Neutral ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

The S&P 500 fell 0.8% on Monday, Feb. 3, as investors reacted to tariffs on major U.S. trading partners while awaiting key earnings and labor market data.

Click here for access. * Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Moderna with a target price of $99. * An analyst from UBS persists with their Buy ...

The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $99.00 to $51.00 in a research note on Wednesday ...